Preventing and reporting adverse drug events: Pharmacovigilance for the clinical nurse specialist

Clinical Nurse Specialist

Volumn 26, Issue 3, 2012, Pages 136-137

  O'Malley, Patricia Anne ^a  

^a MIAMI VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG SURVEILLANCE PROGRAM; MANPOWER; MEDICATION ERROR; NURSING DISCIPLINE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; MEDICATION ERRORS; SPECIALTIES, NURSING;

EID: 84859898848     PISSN: 08876274     EISSN: 15389782     Source Type: Journal    
DOI: 10.1097/NUR.0b013e31825317c4     Document Type: Short Survey

References (12)

1. Prakash B, Singh G. Pharmacovigilance: Scope for a dermatologist. Indian J Dermatol. 2011;56(5):490-493.
2. Barker CI, Talbot JC, Aronson JK. Selected national pharmacovigilance websites: An analysis of contents. Drug Saf. 2012; 35(2):141-148.
3. Xiang Y, Xie Y, Yi D. Pharmacovigilance of major pharmaceutical innovation. Zhonggo Zhong Yao Za Zhi. 2011:36(20):2831-2835.
4. Adverse Events Reporting System (AERS). US Food and Drug Administration. US Department of Health and Human Services. http:// www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/ Surveillance/AdverseDrugEffects/ default.htm. Accessed February 21, 2012.
5. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. US Food and Drug Administration. US Department of Health and Human Services. http://www.fda.gov/ Safety/MedWatch/default.htm. Accessed February 21, 2012.
6. Reporting Serious Problems to FDA. US Food and Drug Administration. US Department of Health and Human Services. http:// www.fda.gov/Safety/MedWatch/ HowToReport/default.htm. Accessed February 21, 2012.
7. Meints A. Adverse drug event reporting and advanced-nursing practice. CNS. 2000;24(6):295-298.
8. AERS Patient Outcomes by Year. US Food and Drug Administration. US Department of Health and Human Services. http:// www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/ Surveillance/AdverseDrugEffects/ ucm070461.htm. Accessed February 21, 2012.
9. Adverse drug events cannot be predicted by patient characteristics or drug type. In: Reducing and Preventing Adverse Drug Events To Decrease Hospital Costs. Research in Action, Issue 1. AHRQ Publication 01-0020. Rockville, MD: Agency for Healthcare Research and Quality; 2001. http://www.ahrq.gov/qual/ aderia/aderia.htm. Accessed February 20, 2012.
10. Pharmacovigilance: Ensuring the safe use of medicines. In: WHO Policy Perspectives on Medicines. October 2004. No. 009. Geneva, Switzerland:World Health Organization; 2004. http://apps.who.int/ medicinedocs/en/d/Js6164e/7. html. Accessed February 20, 2012.
11. Interventions and nursing care strategies. Reducing adverse drug events. In: Evidence-Based Geriatric Nursing Protocols for Best Practice. Rockville MD: National Guideline Clearinghouse. Agency for Healthcare Research and Quality (AHRQ) Web site. http://www.guideline.gov. Accessed February 20, 2012.
12. Ehrenpreis ED, Sifuentes H, Ehrenpreis JE, Smith ZL, Marshall ML. Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants. Expert Opin Drug Saf. 2012;11(2):177-183.